- Home
- VIVS vs INM Comparison
VIVS vs INM Comparison
Compare VIVS & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- INM
- Stock Information
- Founded
- VIVS 2007
- INM 1981
- Country
- VIVS United States
- INM Canada
- Employees
- VIVS N/A
- INM N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- VIVS Health Care
- INM Health Care
- Exchange
- VIVS Nasdaq
- INM Nasdaq
- Market Cap
- VIVS 4.7M
- INM 4.4M
- IPO Year
- VIVS N/A
- INM N/A
- Fundamental
- Price
- VIVS $2.51
- INM $2.11
- Analyst Decision
- VIVS
- INM
- Analyst Count
- VIVS 0
- INM 0
- Target Price
- VIVS N/A
- INM N/A
- AVG Volume (30 Days)
- VIVS 763.1K
- INM 42.3K
- Earning Date
- VIVS 11-07-2025
- INM 09-29-2025
- Dividend Yield
- VIVS N/A
- INM N/A
- EPS Growth
- VIVS N/A
- INM N/A
- EPS
- VIVS N/A
- INM N/A
- Revenue
- VIVS $142,000.00
- INM $4,920,990.00
- Revenue This Year
- VIVS $42.38
- INM N/A
- Revenue Next Year
- VIVS $15.42
- INM N/A
- P/E Ratio
- VIVS N/A
- INM N/A
- Revenue Growth
- VIVS 94.52
- INM N/A
- 52 Week Low
- VIVS $1.41
- INM $1.72
- 52 Week High
- VIVS $21.96
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- VIVS 63.18
- INM 35.28
- Support Level
- VIVS $1.83
- INM $2.22
- Resistance Level
- VIVS $3.10
- INM $2.25
- Average True Range (ATR)
- VIVS 0.33
- INM 0.08
- MACD
- VIVS 0.06
- INM 0.00
- Stochastic Oscillator
- VIVS 57.25
- INM 26.67
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.